SNPS

Synopsys closed the session at $430.14, up 1.81% from the previous day. The move shows a modest gain amid a market dip.

According to the average brokerage recommendation (ABR), one should invest in Synopsys (SNPS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Morgan Stanley says Synopsys’ shift to AI‑focused design tools and a usage‑based licensing model isn’t fully priced in. The bank highlights potential tighter revenue alignment with chip and system design activity.

Synopsys ended the latest session at $422.48, down 6.36% from the prior close. The decline is steeper than the broader market.

Morgan Stanley claims Synopsys is undervalued because the market overlooks its AI revenue potential.

Morgan Stanley’s Lee Simpson keeps an Overweight rating on Synopsys and lifts the price target from $500 to $574.

Synopsys builds the software that powers every chip designed for AI, and analysts are practically falling over each other to buy it. But the real question is whether the tailwinds behind this under-the-radar pick can push a modest investment into life-changing territory before 2030.

Synopsys announced a $1 billion accelerated share buyback after Investor Day. Analysts raised price targets following the buyback and new deals with Amazon and OpenAI.